Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multi-national, Multi-center, Parallel-group, Phase 2b Assessing ART-123's Effect on Preventing Sensory Symptoms of OIPN in Unresectable mCRC Subjects Receiving Oxaliplatin-containing Chemo
Conditions
Interventions
thrombomodulin alfa
Placebo
Start Date
October 1, 2021
Primary Completion Date
April 1, 2023
Completion Date
July 1, 2024
Last Updated
February 18, 2022
NCT07352514
NCT07064798
NCT07164950
NCT06994507
NCT04633655
NCT04970121
Lead Sponsor
Veloxis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions